Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

109.35 +0.95 (+0.88%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis Ag ADR

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
42 43 Next >
3 Pharma Stocks That Are Too Cheap to Ignore
Many stocks are ridiculously expensive right now -- but not these three. 
Via The Motley Fool
Big Data in the Healthcare & Pharmaceutical Market Is Going to Boom : Bayer, Pfizer, Novartis
How to reach that market place and its associated audience with current marketing efforts? Benchmark now the competitive efforts with high growth emerging players and leaders of Big Data in the... 
Via SBWire
Tuesday Markets Coverage
GE was up on hopes for cheaper oil. But most stocks were down on oil price hike fears. 
Via Talk Markets
Novartis May Have Buyer(s) For Its Sandoz Unit - Report
According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase the Novartis AG... 
Via Benzinga
How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022
Alnylam is working on a drug that could tackle transthyretin cardiomyopathy. 
Via Investor's Business Daily
Extended Wear Contact Lenses Market to See Huge Growth by 2026: Johnson and Johnson Vision Care, Novartis, Menicon
Global Extended Wear Contact Lenses Market Report - Production and Consumption Professional Analysis (Impact of COVID-19) is latest research study released by HTF MI evaluating the market risk side... 
Via SBWire
1 Cancer Stock on Buyout Watch in 2022
Cardiff Oncology is a prime takeover target heading into 2022. 
Via The Motley Fool
Exposures COVID-19
Regenerative Medicine Market Worth $17.9 Billion by 2025 - Major Statistics & Growth Dynamics
Northbrook, IL -- (SBWIRE) -- 11/19/2021 -- Regenerative Medicine Market Research Report Provides Crucial Industry Insights. Industry to Witness a Steady Growth in Near Future. 
Via SBWire
North America Pharmaceutical Logistics Supply Chain, Market Trends, and Forecast – Exclusive Report by Mordor Intelligence
Via AB Newswire
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... 
Via Benzinga
Malaria Diagnostics Market To Make Great Impact In Forecast Period 2019-2026 | Grand View Research, Inc.
Via AB Newswire
See Why Molecular Partners Shares Dropped To 52-Week Low During Tuesday Premarket?
Molecular Partners AG (NASDAQ: MOLN) has announced that a planned futility analysis of ensovibep in the Phase 3 ACTIV-3 study has not met the thresholds required to continue... 
Via Benzinga
Johnson & Johnson Pops As It Announces The Biggest Split In Health Care
Johnson & Johnson will split its consumer health unit into a publicly traded company. 
Via Investor's Business Daily
This Company's Innovative Targeted Radiation Therapy Could Offer Potential Hope for Cancer Patients
Photo by National Cancer Institute on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a... 
Via Benzinga
Biosimilars Market worth $44.7 billion by 2026 – Key Players are Novartis AG (Switzerland), Pfizer, Inc. (US)
Via AB Newswire
Biosimilars Market Worth $44.7 Billion by 2026 - Size, Industry Trends, Key Players and Forecast
Northbrook, IL -- (SBWIRE) -- 11/10/2021 -- Biosimilars Market Research Report Gives in Detailed Analysis of Industry Segments, Opportunities, Growth and Size That Will Help Your Business Grow. 
Via SBWire
Topics Intellectual Property
Exposures Intellectual Property
Finance, Legal and Sustainability Professionals at European Listed Companies to Discuss How to Articulate Material ESG Issues
SOURCE: IR Magazine 
Via 3BL Media
Novartis Dumps Another Bispecific Candidate From Xencor Deal
Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia. The... 
Via Benzinga
PixelMEDIA and Docmation Continue Focus on Ecommerce with GearsCRM
GearsCRM joins Pixel and Docmation to build a combined organization for delivery of a complete ecommerce solution on Salesforce. 
Via PR Leap
The Old Lady Of Threadneedle Street
US markets are up on better jobs growth reported for October today. 
Via Talk Markets
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
+15% CAGR & COVID-19 Impact on Difluprednate Market Can See 451 Million by 2027 Major Novartis, Ajanta Pharma, Sun Pharmaceutical, General Pharmaceuticals, Orchidia
This report presents a comprehensive overview, market shares, and growth opportunities of Difluprednate market by product type, application, key manufacturers and key regions and countries. 
Via SBWire
Exposures COVID-19
Biopharmaceuticals Market Is Set to Experience a Revolutionary Growth in Future
Edison, NJ -- (SBWIRE) -- 11/05/2021 -- HTF Market Intelligence added research publication document on Global Biopharmaceuticals Market breaking major business segments and highlighting wider level... 
Via SBWire
Topics Supply Chain
Exposures Supply Chain
64 Stocks Moving In Friday's Mid-Day Session
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; US Economy Adds 531,000 Jobs
Following the market opening Friday, the Dow traded up 0.84% to 36,429.04 while the NASDAQ rose 0.68% to 16,049.24. The S&P also rose, gaining 0.74% to 4,714.85. The U.S. has... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Why Did Deciphera Stock Plunged 70% Today?
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) stock plunged to a 52-week after announcing disappointing results from the INTRIGUE Phase 3 study of Qinlock in... 
Via Benzinga
Novartis' Iptacopan Meets Primary Endpoint Goal In Rare Kidney Disease Trial
Novartis AG (NYSE: NVS) has announced Phase 2 trial data of iptacopan, a selective factor B inhibitor, in patients with C3 glomerulopathy (C3G). In C3G, an overly-active... 
Via Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
Specialty Pharmaceutical Market to Witness Massive Growth by 2028 : Pfizer, Roche, Amgen, AbbVie
Stay up-to-date with Specialty Pharmaceutical Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Exposures COVID-19
Therapeutic Radiopharmaceuticals Market May Set Epic Growth Story : Dongcheng, Q BioMed, Lantheus
Stay up-to-date with Therapeutic Radiopharmaceuticals Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Topics Supply Chain
Exposures Supply Chain
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.